Modern representation of CAR T-cell therapy
Автор: Kuvshinov A. Yu., Voloshin S. V., Kuzyaeva A. A., Shuvaev V. A., Mikhaleva M. A., Martynkevich I. S., Chechetkin A. V., Bessmeltsev S. S.
Журнал: Вестник гематологии @bulletin-of-hematology
Рубрика: Обзор литературы
Статья в выпуске: 2 т.15, 2019 года.
Бесплатный доступ
Adoptive immunotherapy is oneof the accepted modern methods of cancertreatment, based on achievements of genetics,molecular biology and immunology and its goalis to repair the normal functioning of antitumorresponse. The basis of this type of therapy is thecreation of tumor-specific cytotoxic lymphocytesexpressing the chimeric antigen receptor (CAR).The treatment of cancer with CAR T-cells istransformed from experimental technology into arapidly developing therapeutic approach with morethan 500 registered clinical trials in hematologicmalignancies and solid tumors. The article presentsa description of biotechnology, the results of clinicaltrials, a discussion of side effects and problems ofthe emergence of tumor resistance, as well as theprospects for further development and introductionof CAR T-cell therapy into routine clinical practice.
Cart-клетка, adoptive immunotherapy, chimericantigen receptor, car t-cell, malignant hematology
Короткий адрес: https://sciup.org/170172533
IDR: 170172533